IIIV enters its fiscal Q2 2026 earnings print today with short sellers meaningfully backing away — yet the ORTEX short score flags this stock as one of the more closely watched names in the lending market.
Short interest has fallen sharply over the past month, dropping 16% to 11.7% of the free float. That retreat is notable: at its recent peak in early April, more than 3.3 million shares were sold short; the figure has since pulled back to around 2.8 million. Borrow costs have followed suit, easing to roughly 0.45% annualised — down 16% on the week and near their lowest level of the past six weeks. Availability has loosened in tandem, with the borrow market sitting well away from the tightest levels seen earlier this year. The picture is one of de-risking, not escalation, ahead of the print.
Options positioning has shifted in the opposite direction. The put/call ratio has climbed to 0.26, more than twice its 20-day average of 0.15 — a meaningful step toward defensiveness for a stock where call-heavy positioning has been the norm. That said, 0.26 remains well below the 52-week high of 0.41, so this is a tilt rather than a full defensive pivot. The stock itself has held up: IIIV gained 4.1% on Thursday alone and is up around 1.6% on the week, closing at $22.91. Correlated peers put in similar or stronger moves — rose 6.5% on the day, gained 7.0% — suggesting the bid is sector-wide rather than stock-specific.
The analyst debate is split between those who see a quality compounding story and those waiting for proof. DA Davidson holds a $35 Buy target, anchored to i3 Verticals' high recurring-revenue mix, public-sector focus, and M&A track record in vertical software. The bull case centres on margin expansion following the divestiture of non-core payment assets and the company's positioning as a sticky, mission-critical software vendor for government clients. Morgan Stanley sits on the other side at Equal-Weight with a $22 target — essentially at today's price — reflecting concerns about organic growth limitations and integration risk from the acquisition strategy. All the analyst data here dates from February 2026, so the mean target of ~$31 represents a ~37% implied upside from current levels, though no fresh coverage has emerged in the three months since. The EPS surprise factor score ranks in the 20th percentile, suggesting the company has not been a consistent beat-and-raise name.
Insider activity has been one-directional. Multiple officers — including the CFO, President, and General Counsel — sold shares in a cluster around February 11, following further sales by a C-level officer in early March. The values are modest (none exceeding $150,000), and the transactions appear routine in size, but the absence of any buying over the 90-day window is a data point the bulls will need the print to address. The ORTEX short score of 74.6 ranks in the 3rd percentile of its universe — meaning the stock is among the most flagged by the short-interest model — even as the actual positioning has been unwinding. Today's print will test whether the fundamental delivery justifies that retreat in bearish conviction, or whether the score was signalling something the shorts saw before they covered.
See the live data behind this article on ORTEX.
Open IIIV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
